Haematological and Bone Marrow Cancers
Haematological cancers are cancers which affect the blood, bone marrow and lymph nodes. The most common types include leukaemias, lymphomas, myelomas and myeloproliferative disorders (MPDs). All affect cell types that are important for regulating the activity of the immune system.
Leukaemias start in blood-forming tissue such as the bone marrow and results in the release of large numbers of abnormal blood cells into the bloodstream. Leukaemias may be classed as acute or chronic and may stem from lymphocytic or myeloid cells. This equates to four subtypes; acute myeloid leukaemia (AML), acute lymphocytic leukaemia (ALL), chronic myeloid leukaemia (CML) and chronic lymphocytic leukaemia (CLL).
Lymphomas impact on lymphocytes and presents as a solid tumour that generally develops in the lymph nodes, spleen, bone marrow or blood. There are two subtypes, Hodgkin lymphoma and non-Hodgkin’s lymphoma. Myelomas lead to an accumulation of plasma cells in bone marrow which impacts on the production of normal blood cells.
Related news and insights
The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the European Commission (EC) has approved a variation to the marketing authorisation for Imbruvica (ibrutinib), extending the approved indication in chronic lymphocytic leukaemia (CLL) to include combination with rituximab for previously untreated adult patients.
Kite Pharma/Gilead Sciences have submitted a supplemental Biologics License Application (sBLA) to the FDA for Yescarta (axicabtagene ciloleucel) for the treatment of relapsed or refractory follicular lymphoma and marginal zone lymphoma - relapsed or refractory indolent non-Hodgkin lymphoma (NHL) - after two or more prior lines of systemic therapy.
GlaxoSmithKline announced the European Commission has granted conditional marketing authorisation for Blenrep (belantamab mafodotin-blmf) as monotherapy for the treatment of multiple myeloma in adult patients who have received at least four prior therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.
This guideline covers the planning and management of end of life and palliative care in for infants, children and young people (aged 0-17 years) with life-limiting conditions. It aims to involve children, young people and their families...
The estimated overall incidence of acute lymphoblastic leukaemia and lymphoblastic lymphoma in Europe is 1.28 per 1 000 000 individuals annually, with significant age-related variations.
You may be interested in...
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive interstitial lung disease. IPF is more common in elderly patients and over time as healthy lung tissue is replaced by altered extracellular matrix (fibrosis) the alveolar architecture is destroyed, leading to decreased lung function and finally respiratory failure and death.
ICRMB 2021: International Conference on Reproductive Medicine and Biology
ICRMB 2021: 15. International Conference on Reproductive Medicine and Biology aims to bring together leading academic scientists, researchers and research scholars to exchange and share their experiences and research results on all aspects of Reproductive Medicine and Biology.
International Conference on Nephrology and Urology
ICNU 2021: 15. International Conference on Nephrology and Urology aims to bring together leading academic scientists, researchers and research scholars to exchange and share their experiences and research results on all aspects of Nephrology and Urology.